Newsroom
November 05, 2019
New Data from Ambry Genetics Show Substantial Increase in Diagnostic Yield, Further Supporting the Routine Use of RNA Genetic Testing for Hereditary Cancer Panels
Based on data from a prospective, nationwide, multi-center pilot, adding RNA genetic testing to DNA testing identified more disease-causing mutations compared to DNA-only testing. Results from a separate study demonstrated that genetic testing results frequently lead to changes in patient care ...
Read More
October 23, 2019
Ambry Genetics Published Data that Finds Adding RNA Genetic Testing Provides More Accurate, Actionable Results for Patients who Receive DNA Testing for Hereditary Cancer Risk
A new study published in JAMA Network Open demonstrates that RNA genetic testing can substantially improve the interpretation of DNA testing results and improve medical care (Aliso Viejo, CA) October 23, 2019: Ambry Genetics® (Ambry), a leading clinical genetics company, announced today the publication ...
Read More
October 15, 2019
New Data from Ambry Genetics Demonstrates Impact of First Major Advancement in Over 10 Years to Increase Diagnostic Yield in Genetic Testing for Hereditary Cancer Risk
In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results. Separate data showed RNA genetic testing’s ability to clarify the interpretation of complex ...
Read More
October 01, 2019
Ambry Genetics Makes Scientific Breakthrough and Launches Paired RNA and DNA Testing for Hereditary Cancer
+RNAinsight™ will help identify thousands more patients at increased risk for cancer (Aliso Viejo, CA) October 1, 2019: Ambry Genetics® (Ambry), a leading clinical genetic testing company, announced today the launch of +RNAinsight™, a major advancement in genetic testing. +RNAinsight enables ...
Read More
August 27, 2019
Ambry Genetics’ Data Reveal that Expanding Genetic Testing Guidelines Could Identify More Patients with Increased Risks of Cancer
Study finds that current guidelines exclude too many and test too narrowly, and reveals several new gene-cancer associations with potential to impact patient care. (Aliso Viejo, CA) August 27, 2019: Ambry Genetics (Ambry), a leading clinical genetics testing company, announced today new opportunities ...
Read More
July 16, 2019
hATTR CompassTM Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic testing and genetic counseling services to people with suspected hereditary ATTR amyloidosis Boston, Mass. and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) – Akcea Therapeutics, Inc. ...
Read More
June 06, 2019
Konica Minolta to Join Global Oncogenic Gene Panel Research
Move Strengthens Konica Minolta’s Advance into Personalized Medicine in Japan with Next-Generation Screening Capabilities TOKYO, Japan (June 6, 2019) - Konica Minolta, Inc. (Konica Minolta) today announces agreement with the University of Tokyo (UTokyo) and the National Cancer Center Japan ...
Read More
May 30, 2019
Research from Ambry Genetics & Mayo Clinic Reveals Differences in the Prevalence of Breast Cancer Genes among Racial and Ethnic Populations
Abstract to be presented at the 2019 American Society of Clinical Oncologists (ASCO) Annual Meeting (Aliso Viejo, CA) May 30, 2019: Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, and Mayo Clinic, have documented significant differences in the prevalence of ...
Read More
May 02, 2019
Ambry Genetics Research Highlights Need for Expanded Genetic Testing Payer Coverage for Patients At-Risk for Hereditary Breast and Ovarian Cancer
Data presented at the 2019 American Society of Breast Surgeons (ASBrS) Annual Meeting (Aliso Viejo, CA) May 2, 2019: Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, will present results documenting discrepancies between U.S. insurer policies for genetic testing ...
Read More
April 09, 2019
Intalere Teams with Ambry Genetics to Offer Healthcare Providers Advanced Genetic Testing for Cancer Risk Assessment
St. Louis (April 9, 2019) - Intalere, the healthcare industry leader in delivering optimal cost, quality and clinical outcomes, today announced a new partnership with Ambry Genetics, a leading clinical genetic testing company. The collaboration will enable Intalere to offer its healthcare providers ...
Read More